Research

CMT Research Database

Can you help with Charcot-Marie-Tooth clinical research? If you have Charcot-Marie-Tooth disease, live in the United Kingdomand would like to […]

Pharnext reports topline results from the pivotal Phase III clinical trial(PREMIER trial) of PXT3003 in Charcot-Marie-Tooth disease type 1A

Pharnext intends to prepare registration and marketing authorizationdossiers for PXT3003, its drug candidate in Charcot-Marie-Tooth diseasetype 1A

Pharnext enters the final stretch for the signature of a licensingagreement for its drug candidate in Charcot-Marie-Tooth disease type 1A(PXT3003), enabling it to capitalize on its assets and put an end to theOCEANE-BSA financing line